On Thursday, 1120 stocks advanced, 2864 declined and 92 remained unchanged, with an advance decline ratio 0.39 on the Bombay Stock Exchange (BSE), indicating negative closing of stocks in broader ...

Pharma stock engaged in manufacturing and distributing of pharmaceutical products gained traction on Thursday’s trading ...

Patients with metastatic castration-sensitive prostate cancer are recommended to be treated with enzalutamide tablets.

Here is a list of stocks that are set to be in focus during Thursday's session, as participants return to trade after a day's ...

Zydus Lifesciences share price will remain in focus on October 3 after the company received tentative approval from the ...

Maruti Suzuki reported a nearly 2% jump in September total sales at 1,84,727 units versus 1,81,343 units in the corresponding ...

Johnson & Johnson today released results of a landmark real-world head-to-head study showing that Erleada (apalutamide) ...

Ahmedabad: Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration ...

Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...